aspirin and Gastroduodenal Ulcer studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"Peptic ulcers in patients receiving aspirin are associated with Helicobacter pylori infection."	9.51	Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. ( Avery, A; Coupland, CAC; Crooks, C; Dumbleton, J; Hawkey, C; Hobbs, FDR; Kendrick, D; Moore, M; Morris, C; Rubin, G; Smith, M; Stevenson, D, 2022)
"Aspirin-related peptic ulcers are a common disorder."	9.16	Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. ( Chen, WC; Ger, LP; Hsu, PI; Lai, KH; Lin, SY; Liu, CP; Mar, GY, 2012)
" We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA."	9.16	Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012)
" As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's."	9.15	Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011)
"Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin."	9.14	Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009)
"Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers."	9.14	Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010)
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."	9.14	Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
"Patients aged > or =60 yr, without baseline gastroduodenal ulcer at endoscopy, who were receiving aspirin 75-325 mg once daily, were randomized to esomeprazole 20 mg once daily or placebo for 26 wk."	9.13	Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. ( Hawkey, C; Karamanolis, D; Labenz, J; Lanas, A; Nauclér, E; Rácz, I; Roda, E; Svedberg, LE; Tchernev, K; van Rensburg, C; van Zanten, SV; Yeomans, N, 2008)
"To evaluate the risk of gastrointestinal (GI) symptoms and ulcers associated to the use of low-dose aspirin (ASA) among patients with rheumatoid arthritis (RA) and osteoarthritis (OA) treated with cyclooxygenase-2 (COX-2) drugs, to clarify the controversy in the literature."	9.12	The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. ( Benito-Garcia, E; Michaud, K; Wolfe, F, 2007)
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain."	9.12	Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007)
"Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients."	9.11	Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004)
"High-dose aspirin therapy for rheumatoid arthritis is frequently associated with severe gastrointestinal injury."	9.06	Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. ( Agrawal, N; Crager, M; Mahowald, M; Miller, S; Montoya, H; Nissen, C; Nutting, E; Robbins, D; Roth, S; Woods, E, 1989)
"Survival analysis techniques were used to compare the long-term incidence of peptic ulceration occurring in fenbufen, indomethacin and aspirin treated patients with a "background" incidence for the whole population."	9.06	A comparison of the incidence of peptic ulceration for fenbufen, indomethacin and aspirin treated patients compared with the general population. ( Cohen, PM, 1986)
"Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations."	9.06	Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986)
" Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%."	8.87	Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011)
"A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)."	8.84	Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007)
"In the prevalent-user design, there was no significant association between low-dose aspirin and gastric ulcer observed in both cohorts."	8.12	Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. ( Brenner, H; Chen, LJ; Holleczek, B; Nguyen, TNM; Schöttker, B; Sha, S, 2022)
"Low-dose aspirin can cause gastric and duodenal ulceration, hereafter called peptic ulcer disease (PUD)."	8.02	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. ( Bourgeois, S; Carr, DF; Deloukas, P; Esume, C; Jorgensen, AL; Morris, AP; Musumba, CO; Penrose, A; Pirmohamed, M; Pritchard, DM; Zhang, JE, 2021)
"To investigate the impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter, and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin."	7.80	Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. ( Chen, A; Chen, HP; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Tsay, FW; Tseng, HH; Wang, PY, 2014)
"In our previous study, the SLCO1B1 521TT genotype and the SLCO1B11b haplotype were significantly associated with the risk of peptic ulcer in patients taking low-dose aspirin* (LDA)."	7.80	Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. ( Fujimura, Y; Fujita, Y; Haruma, K; Murao, T; Nishio, K; Sakakibara, T; Shiotani, A, 2014)
" We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months."	7.79	Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013)
"Little is known about how discontinuation of low-dose aspirin therapy after peptic ulcer bleeding affects patient mortality or acute cardiovascular events."	7.79	Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. ( Bottai, M; Derogar, M; Lu, Y; Lundell, L; Orsini, N; Sadr-Azodi, O; Sandblom, G, 2013)
"SLCO1B1 1b haplotype may identify patients at increased risk for aspirin-induced peptic ulcer."	7.78	Association of SLCO1B1 1b with peptic ulcer amongst Japanese patients taking low-dose aspirin. ( Haruma, K; Kamada, T; Kusunoki, H; Manabe, N; Murao, T; Sakakibara, T; Shiotani, A; Tarumi, K, 2012)
"This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease."	7.78	[Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012)
"To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents."	7.77	Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. ( Kadota, J; Murakami, K; Tamura, A, 2011)
"We classified 1,041 gastroduodenal ulcer patients into three groups [patients taking LDA (group A), patients taking nonaspirin nonsteroidal anti-inflammatory drug (NSAID) (group N), and patients taking neither aspirin nor nonaspirin NSAID (group C)] and 241 bleeding gastroduodenal ulcer patients into three corresponding groups (groups a, n, and c)."	7.76	Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. ( Hirayama, T; Honda, A; Ikegami, T; Ito, M; Iwamoto, J; Matsuzaki, Y; Mizokami, Y; Saito, Y; Shimokobe, K, 2010)
"The risk for erosive esophagitis (EE) with low-dose aspirin (ASA) remains unknown, especially among Japanese patients."	7.76	Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. ( Abe, K; Ebato, T; Hattori, K; Ishii, T; Isono, A; Kuyama, Y; Mishina, Y; Yamamoto, T, 2010)
"To clarify the gender differences about the clinical features and risk factors of low-dose aspirin (LDA) (81-100 mg daily)-associated peptic ulcer in Japanese patients."	7.76	Gender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients. ( Atsukawa, K; Chiba, H; Hoshino, E; Imajyo, K; Inamori, M; Nakajima, A; Nonaka, T; Okada, K; Sakaguchi, T; Shiba, T; Takahashi, H, 2010)
"To investigate the usefulness of anti-ulcer drugs for the prevention and treatment of low-dose aspirin-induced peptic ulcer."	7.75	Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. ( Arai, S; Imai, Y; Inao, M; Ishikawa, K; Mochida, S; Nagoshi, S; Nakashima, S; Nakayama, N; Ota, S; Yoshino, K, 2009)
" This study aimed to examine effects of corpus atrophy and the genotypes of genes related to peptic ulcer, including IL-1beta, on risk of aspirin ulcer."	7.75	The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. ( Fujita, M; Haruma, K; Hata, J; Imamura, H; Kamada, T; Nishi, R; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y, 2009)
"To evaluate the incidence and mortality related to peptic ulcer perforation while considering the intake of low-dose aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)."	7.74	Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. ( Angerson, WJ; Gilmour, D; McCloskey, C; Morran, CG; Prasad, R; Taha, AS, 2008)
"This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy."	7.74	Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008)
"A total of 991 patients with coronary artery disease (CAD) on low-dose aspirin were prospectively followed-up for two years for the occurrence and clinical features of first hospitalized episode of UGIB."	7.73	Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Lai, KC; Lam, KF; Lau, CP; Lee, PY; Li, SW; Ng, M; Ng, W; Tse, HF; Wong, WM, 2006)
"During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited."	7.72	High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003)
"Although administration of gastroprotective drugs may reduce the risk of peptic ulcers associated with the chronic use of non-steroidal anti-inflammatory drugs or aspirin, no consensus exists as to whether this co-therapy is effective for short-term prevention, particularly in old age."	7.72	Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. ( Andriulli, A; Cascavilla, L; Di Mario, F; Franceschi, M; Leandro, G; Longo, MG; Niro, V; Paris, F; Pilotto, A; Scarcelli, C, 2004)
"Non-steroidal anti-inflammatory drug and aspirin (here collectively called NSAIDs) use is the second most common aetiologic factor for peptic ulcer disease and a major factor for peptic ulcer complications."	7.71	Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. ( Färkkilä, M; Juhola, M; Mäntynen, T; Sipponen, P; Voutilainen, M, 2001)
"We studied 30 patients with postsurgical ulcer and aspirin abuse."	7.70	Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998)
"To compare the outcome of 76 patients who presented with severe peptic ulcer haemorrhage whilst taking nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin with that of 112 patients who were not taking these drugs and who developed peptic ulcer haemorrhage over the same time period."	7.69	The outcome of peptic ulcer haemorrhage in relation to consumption of nonsteroidal anti-inflammatory drugs or aspirin. ( Choudari, CP; Elton, RA; Palmer, KR, 1994)
"Because aspirin (ASA) may affect peptic ulcer healing through actions on platelets (for example, by inhibiting release of growth factors), human foreskin fibroblast mitogenesis was used for two bioassays (24-h growth with 3H-thymidine incorporation and 5- to 6-day cell proliferation) for serum derived from collagen-aggregated platelet-rich plasma (PRP) or platelet-poor plasma (PPP) or from clotted whole blood (WBS)."	7.69	Ingestion of aspirin prevents platelet-induced human fibroblast growth. Implications for peptic ulcer healing. ( Haggerty, P; Hirschowitz, BI; Lanas, A, 1994)
"Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily."	7.67	Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989)
"Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1."	6.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
"The misoprostol/aspirin-treated group had significantly (P < 0."	6.67	Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. ( Boudrieau, RJ; Labato, MA; Matz, ME; Murtaugh, RJ, 1993)
" When used long term, aspirin has significant adverse effects and is poorly tolerated."	6.40	Use and safety of aspirin in the chemoprevention of colorectal cancer. ( Singh, AK; Trotman, BW, 1998)
"Peptic ulcers in patients receiving aspirin are associated with Helicobacter pylori infection."	5.51	Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. ( Avery, A; Coupland, CAC; Crooks, C; Dumbleton, J; Hawkey, C; Hobbs, FDR; Kendrick, D; Moore, M; Morris, C; Rubin, G; Smith, M; Stevenson, D, 2022)
" pylori infection, use or abuse (often surreptitious) of high dose non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin (ASA) are the two major causes of true refractory ulcers."	5.41	Advances in the pharmacotherapeutic management of refractory peptic ulcers. ( Borao Laguna, C; Lanas, A, 2023)
"Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin."	5.40	Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014)
"Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study."	5.27	Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018)
"To evaluate if esomeprazole prevents recurrent peptic ulcer in adult patients with a history of peptic ulcer receiving low-dose acetylsalicylic acid (ASA, aspirin) for cardiovascular protection in East Asia."	5.19	Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. ( Chang, CY; Chiang, CE; Chiba, T; Choi, MG; Date, M; Fukushima, Y; Goto, S; Hori, M; Kim, HS; Kinoshita, Y; Lin, JT; Miwa, H; Okada, Y; Sugano, K, 2014)
" Patients with Helicobacter pylori infection and a history of peptic ulcer were assigned dual antiplatelet combination with omeprazole."	5.17	Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. ( Chen, G; Du, Y; Hang, L; Ma, B, 2013)
"Aspirin-related peptic ulcers are a common disorder."	5.16	Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. ( Chen, WC; Ger, LP; Hsu, PI; Lai, KH; Lin, SY; Liu, CP; Mar, GY, 2012)
" We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA."	5.16	Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012)
" As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's."	5.15	Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011)
"Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin."	5.14	Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009)
"Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers."	5.14	Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010)
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."	5.14	Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
"To compare the therapeutic effects of proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) on gastroduodenal ulcers under continuous use of low-dose aspirin."	5.14	Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. ( Kato, M; Nema, H, 2010)
"Patients aged > or =60 yr, without baseline gastroduodenal ulcer at endoscopy, who were receiving aspirin 75-325 mg once daily, were randomized to esomeprazole 20 mg once daily or placebo for 26 wk."	5.13	Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. ( Hawkey, C; Karamanolis, D; Labenz, J; Lanas, A; Nauclér, E; Rácz, I; Roda, E; Svedberg, LE; Tchernev, K; van Rensburg, C; van Zanten, SV; Yeomans, N, 2008)
"To evaluate the risk of gastrointestinal (GI) symptoms and ulcers associated to the use of low-dose aspirin (ASA) among patients with rheumatoid arthritis (RA) and osteoarthritis (OA) treated with cyclooxygenase-2 (COX-2) drugs, to clarify the controversy in the literature."	5.12	The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. ( Benito-Garcia, E; Michaud, K; Wolfe, F, 2007)
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain."	5.12	Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007)
"Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients."	5.11	Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004)
"The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double-blind, 52-week study of lumiracoxib 400 mg once daily (two to four times the recommended dose for osteoarthritis) versus naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with osteoarthritis."	5.11	Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. ( Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P, 2004)
"To evaluate the relative risk for peptic ulcer disease that is associated with the use of nonaspirin nonsteroidal anti-inflammatory drugs."	5.07	Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. ( Daugherty, JR; Griffin, MR; Piper, JM; Ray, WA; Snowden, M, 1991)
"High-dose aspirin therapy for rheumatoid arthritis is frequently associated with severe gastrointestinal injury."	5.06	Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. ( Agrawal, N; Crager, M; Mahowald, M; Miller, S; Montoya, H; Nissen, C; Nutting, E; Robbins, D; Roth, S; Woods, E, 1989)
"Survival analysis techniques were used to compare the long-term incidence of peptic ulceration occurring in fenbufen, indomethacin and aspirin treated patients with a "background" incidence for the whole population."	5.06	A comparison of the incidence of peptic ulceration for fenbufen, indomethacin and aspirin treated patients compared with the general population. ( Cohen, PM, 1986)
"Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations."	5.06	Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986)
" Gastrointestinal side effects with benoxaprofen compared favorably to those reported during aspirin and ibuprofen therapy, with peptic ulcers reported in 0."	5.05	Long-term safety of benoxaprofen. ( Mikulaschek, WM, 1980)
"Owing to wide-spread use, low-dose aspirin (LDA) produces a substantial amount of peptic ulcer disease."	5.01	Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. ( Grigg, SE; Sarri, GL; Yeomans, ND, 2019)
" pylori) infection, nonsteroidal anti-inflammatory drugs (NSAID) or low dose aspirin (ASA) use significantly and independently increased the risk for the development of peptic ulcer disease."	4.90	Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. ( Gargallo, CJ; Lanas, A; Sostres, C, 2014)
" Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%."	4.87	Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011)
" pylori infection and low-dose aspirin (LDA) are not only independent causal factors of peptic ulcer and gastrointestinal bleeding, they also have synergistic and additive effects."	4.86	[Influence of H. pylori infection on upper gastrointestinal damage]. ( Fukuzawa, M; Kawai, T; Moriyasu, F; Yamashina, A, 2010)
"A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)."	4.84	Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007)
"Based on current references four clinical scenarios were discussed and different management strategies were compared for secondary and primary prophylaxis of ulcer or peptic ulcer bleeding under continuous therapy with non-steroidal antiinflammatory drugs (NSAID) or low-dose-aspirin, for H."	4.82	[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. ( Ittel, TH; Limmer, S; Wietholtz, H, 2003)
"Use of low-dose aspirin is associated with an increased risk of gastroduodenal ulcers and upper gastrointestinal bleeding."	4.82	[Prevention of gastroduodenal complications in patients taking low-dose aspirin]. ( Chaussade, S; Chryssostalis, A; Marck, G; Sibilia, J, 2004)
" Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development."	4.81	[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001)
"Most peptic ulcers not due to Helicobacter pylori are caused by non-steroidal anti-inflammatory drugs (NSAID), among which an important subset are due to vascular protective ("low-dose") aspirin therapy."	4.81	Management of peptic ulcer disease not related to Helicobacter. ( Yeomans, ND, 2002)
"Long-term use of aspirin and severity of cerebral infarction are risk factors for gastrointestinal bleeding in cerebral infarction patients receiving dual antiplatelet therapy."	4.31	Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy. ( Huang, J; Liao, F; Shu, X; Tang, J, 2023)
"In the prevalent-user design, there was no significant association between low-dose aspirin and gastric ulcer observed in both cohorts."	4.12	Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. ( Brenner, H; Chen, LJ; Holleczek, B; Nguyen, TNM; Schöttker, B; Sha, S, 2022)
"Low-dose aspirin can cause gastric and duodenal ulceration, hereafter called peptic ulcer disease (PUD)."	4.02	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. ( Bourgeois, S; Carr, DF; Deloukas, P; Esume, C; Jorgensen, AL; Morris, AP; Musumba, CO; Penrose, A; Pirmohamed, M; Pritchard, DM; Zhang, JE, 2021)
" Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers."	3.85	The risk of lower gastrointestinal bleeding in low-dose aspirin users. ( Chen, WC; Chuah, SK; Hsu, PI; Huang, YT; Lin, KH; Sun, WC; Tsai, TJ; Wu, DC, 2017)
"The main innovations of the latest meeting of the Gastroenterological Association (2016) concerning upper gastrointestinal bleeding from the clinician's perspective can be summarised as follows: a) The Glasgow-Blatchford scale has the best accuracy in predicting the need for surgical intervention and hospital mortality; b) Prognostic scales for non-variceal upper gastrointestinal bleeding are also useful for lower gastrointestinal bleeding; c) Preliminary data suggest that treatment with hemospray does not seem to be superior to current standard treatment in controlling active peptic ulcer bleeding; d) Either famotidine or a proton pump inhibitor may be effective in preventing haemorrhagic recurrence in patients taking aspirin, but this finding needs to be confirmed in further studies; e) There was confirmation of the need to re-introduce antiplatelet therapy as early as possible in patients with antiplatelet-associated gastrointestinal bleeding in order to prevent cardiovascular mortality; f) Routine clinical practice suggests that gastrointestinal or cardiovascular complications with celecoxib or traditional NSAIDs are very low; g) Dabigatran is associated with an increased incidence of gastrointestinal bleeding compared with apixaban or warfarin."	3.83	Advances in gastrointestinal bleeding. ( Lanas, Á, 2016)
"Gastroduodenal ulcer and erosion are common in Japanese patients taking low dose aspirin for cardioprotection."	3.80	Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2014)
"The Japanese health insurance system approved the use of proton pump inhibitors (PPIs) for the prevention of peptic ulcers in patients using low-dose aspirin (LDA) and/or non-steroidal anti-inflammatory drugs (NSAIDs)."	3.80	Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. ( Fukuda, S; Mikami, T; Nakagawa, S; Sakamoto, Y; Shimoyama, T, 2014)
"Increased incidence of coronary artery disease has led to the increased use of dual antiplatelet therapy composed of aspirin and clopidogrel."	3.80	[Clinical impact of dual antiplatelet therapy on peptic ulcer disease]. ( Ahn, DG; Kim, BJ; Kim, JG; Kim, JW, 2014)
"To investigate the impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter, and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin."	3.80	Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. ( Chen, A; Chen, HP; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Tsay, FW; Tseng, HH; Wang, PY, 2014)
"Underusers were defined as persons taking nonselective NSAIDs who were at risk of peptic ulcer disease (PUD; because of current warfarin or glucocorticoid use or history of PUD) and not using a proton pump inhibitor (PPI) or persons taking cyclooxygenase 2 (COX-2) selective NSAIDs and aspirin who were at risk of PUD (having at least one risk factor) and not using a PPI."	3.80	Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. ( Bauer, DC; Boudreau, R; Donohue, JM; Hanlon, JT; Marcum, ZA; Newman, AB; Perera, S; Shorr, RI; Simonsick, EM; Strotmeyer, ES, 2014)
"In our previous study, the SLCO1B1 521TT genotype and the SLCO1B11b haplotype were significantly associated with the risk of peptic ulcer in patients taking low-dose aspirin* (LDA)."	3.80	Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. ( Fujimura, Y; Fujita, Y; Haruma, K; Murao, T; Nishio, K; Sakakibara, T; Shiotani, A, 2014)
" We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months."	3.79	Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013)
"Little is known about how discontinuation of low-dose aspirin therapy after peptic ulcer bleeding affects patient mortality or acute cardiovascular events."	3.79	Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. ( Bottai, M; Derogar, M; Lu, Y; Lundell, L; Orsini, N; Sadr-Azodi, O; Sandblom, G, 2013)
"SLCO1B1 1b haplotype may identify patients at increased risk for aspirin-induced peptic ulcer."	3.78	Association of SLCO1B1 1b with peptic ulcer amongst Japanese patients taking low-dose aspirin. ( Haruma, K; Kamada, T; Kusunoki, H; Manabe, N; Murao, T; Sakakibara, T; Shiotani, A; Tarumi, K, 2012)
"Low-dose aspirin (ASA) has emerged as one of the most important causes of peptic ulcer bleeding in developed countries."	3.78	Anti-platelet therapy and managing ulcer risk. ( Chan, FK, 2012)
" In the management of aspirin-related uncomplicated peptic ulcers in patients requiring antiplatelet therapies, continuing aspirin plus a powerful proton pump inhibitor is the choice of treatment."	3.78	New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. ( Hsu, PI, 2012)
"Recent data from Western countries indicate that the aetiology of peptic ulcer disease (PUD) is changing as the prevalence of Helicobacter pylori is decreasing while the use of low-dose aspirin (LDA, ≤325 mg/day) is increasing."	3.78	The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. ( Hopkins, M; Jorgensen, A; Moorcroft, J; Musumba, C; Pirmohamed, M; Pritchard, DM; Sutton, L; Van Eker, D, 2012)
"This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease."	3.78	[Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012)
"The frequencies of hemorrhagic spots, erosions and peptic ulcers in the symptomatic clopidogrel users were 25%, 39% and 39%, respectively."	3.78	Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. ( Chan, HH; Chang, SN; Hsiao, SH; Hsu, PI; Huang, HR; Lai, KH; Lin, CH; Lin, CK; Lin, KH; Liu, CP; Tsai, TJ; Tsay, FW; Wang, HM; Wang, KM; Yu, HC, 2012)
"We have previously shown that co-treatment of angiotensin type 1 receptor (AT1R) blocker (ARB) or angiotensin converting enzyme (ACE) inhibitor seem to reduce peptic ulcer among patients taking low dose aspirin."	3.77	Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. ( Haruma, K; Kamada, T; Matsumoto, H; Murao, T; Nishi, R; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y, 2011)
"To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents."	3.77	Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. ( Kadota, J; Murakami, K; Tamura, A, 2011)
" However, it has been only in the last half century that evidence has emerged that aspirin causes reproducible acute and superficial injury to the gastric and duodenal mucosa, and is an important cause of complicated and uncomplicated peptic ulcer."	3.77	Aspirin: old drug, new uses and challenges. ( Yeomans, ND, 2011)
"We classified 1,041 gastroduodenal ulcer patients into three groups [patients taking LDA (group A), patients taking nonaspirin nonsteroidal anti-inflammatory drug (NSAID) (group N), and patients taking neither aspirin nor nonaspirin NSAID (group C)] and 241 bleeding gastroduodenal ulcer patients into three corresponding groups (groups a, n, and c)."	3.76	Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. ( Hirayama, T; Honda, A; Ikegami, T; Ito, M; Iwamoto, J; Matsuzaki, Y; Mizokami, Y; Saito, Y; Shimokobe, K, 2010)
"The risk for erosive esophagitis (EE) with low-dose aspirin (ASA) remains unknown, especially among Japanese patients."	3.76	Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. ( Abe, K; Ebato, T; Hattori, K; Ishii, T; Isono, A; Kuyama, Y; Mishina, Y; Yamamoto, T, 2010)
"Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease."	3.76	Primary prevention of ulcers in patients taking aspirin or NSAIDs. ( , 2010)
"To clarify the gender differences about the clinical features and risk factors of low-dose aspirin (LDA) (81-100 mg daily)-associated peptic ulcer in Japanese patients."	3.76	Gender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients. ( Atsukawa, K; Chiba, H; Hoshino, E; Imajyo, K; Inamori, M; Nakajima, A; Nonaka, T; Okada, K; Sakaguchi, T; Shiba, T; Takahashi, H, 2010)
"PPI was superior to H2-receptor antagonist for prevention of peptic ulcer, and cotreatment with AT1 receptor blocker or ACE inhibitor seemed to reduce peptic ulcer among patients taking low-dose aspirin."	3.75	Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. ( Haruma, K; Hata, J; Imamura, H; Kamada, T; Kusunoki, H; Manabe, N; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y, 2009)
"To investigate the usefulness of anti-ulcer drugs for the prevention and treatment of low-dose aspirin-induced peptic ulcer."	3.75	Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. ( Arai, S; Imai, Y; Inao, M; Ishikawa, K; Mochida, S; Nagoshi, S; Nakashima, S; Nakayama, N; Ota, S; Yoshino, K, 2009)
" This study aimed to examine effects of corpus atrophy and the genotypes of genes related to peptic ulcer, including IL-1beta, on risk of aspirin ulcer."	3.75	The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. ( Fujita, M; Haruma, K; Hata, J; Imamura, H; Kamada, T; Nishi, R; Sakakibara, T; Shiotani, A; Tarumi, K; Yamanaka, Y, 2009)
"This study was conducted to compare the risk of recurrent hospitalization for major gastrointestinal (GI) complications (peptic ulcer, bleeding, and perforation) in patients at high GI risk who require ongoing antiplatelet therapy (aspirin [acetylsalicylic acid] or clopidogrel) with or without proton pump inhibitors (PPIs)."	3.75	A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. ( Chang, PY; Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW, 2009)
"To evaluate the incidence and mortality related to peptic ulcer perforation while considering the intake of low-dose aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)."	3.74	Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. ( Angerson, WJ; Gilmour, D; McCloskey, C; Morran, CG; Prasad, R; Taha, AS, 2008)
"This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy."	3.74	Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008)
"05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium."	3.74	Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007)
" The records of H pylori status (CLO-test), endoscopic findings of GU, DU and gastritis, personal habits (smoking, alcohol intake) and medication [non-steroidal anti-inflammatory drugs (NSAIDs), aspirin intake] were analyzed using multi-way frequency analysis."	3.74	H pylori infection and other risk factors associated with peptic ulcers in Turkish patients: a retrospective study. ( Abasiyanik, MF; Bayyurt, N; Salih, BA; Sander, E, 2007)
"The present study was designed to investigate anti-ulcerogenic property of ethanolic extract of Desmodium gangeticum (DG) against cold restraint (CRU, 2 hr cold restraint stress), aspirin (ASP, 150 mg/kg orally), alcohol (AL, absolute alcohol 1 ml/200gm) and pyloric ligation (PL, 4 hr pylorus ligation) induced gastric ulcer models in Sprague Dawley rats, and histamine (HST, 0."	3.73	Desmodium gangeticum: a potent anti-ulcer agent. ( Chauhan, VS; Dharmani, P; Maurya, R; Mishra, PK; Palit, G, 2005)
"To determine the risk of peptic ulcer upper gastrointestinal bleeding (UGIB) associated with the use of coxibs, traditional NSAIDs, aspirin or combinations of these drugs in clinical practice."	3.73	Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. ( Arroyo, MT; Bástida, G; Borda, F; de Argila, CM; Feu, F; García-Rodríguez, LA; Gomollón, F; González-Pérez, A; Güell, M; Lanas, A; Piqué, JM; Quintero, E; Rodrigo, L; Santolaria, S; Zapata, E, 2006)
"A total of 991 patients with coronary artery disease (CAD) on low-dose aspirin were prospectively followed-up for two years for the occurrence and clinical features of first hospitalized episode of UGIB."	3.73	Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. ( Chen, WH; Cheng, X; Lai, KC; Lam, KF; Lau, CP; Lee, PY; Li, SW; Ng, M; Ng, W; Tse, HF; Wong, WM, 2006)
"Over 60% of aspirin users are above 60 years of age, 4 to 6% have a recent history of peptic ulcers and over 13% use other non-steroidal anti-inflammatory drugs."	3.73	Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. ( García Rodríguez, LA; Hernández-Díaz, S, 2006)
"During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited."	3.72	High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003)
"Although administration of gastroprotective drugs may reduce the risk of peptic ulcers associated with the chronic use of non-steroidal anti-inflammatory drugs or aspirin, no consensus exists as to whether this co-therapy is effective for short-term prevention, particularly in old age."	3.72	Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. ( Andriulli, A; Cascavilla, L; Di Mario, F; Franceschi, M; Leandro, G; Longo, MG; Niro, V; Paris, F; Pilotto, A; Scarcelli, C, 2004)
", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting."	3.71	Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001)
"Non-steroidal anti-inflammatory drug and aspirin (here collectively called NSAIDs) use is the second most common aetiologic factor for peptic ulcer disease and a major factor for peptic ulcer complications."	3.71	Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. ( Färkkilä, M; Juhola, M; Mäntynen, T; Sipponen, P; Voutilainen, M, 2001)
"We studied 30 patients with postsurgical ulcer and aspirin abuse."	3.70	Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998)
" On the other hand, the non-selective NOS inhibitor L-NAME but not aminoguanidine (a relatively selective inhibitor of iNOS), significantly potentiated the acid secretory and mucosal ulcerogenic responses in the stomach but reduced the duodenal damage in response to hypothermia, the effects being antagonized by co-administration of L-arginine."	3.70	Roles of endogenous prostaglandins and nitric oxide in gastroduodenal ulcerogenic responses induced in rats by hypothermic stress. ( Araki, H; Mizoguchi, H; Sugamoto, S; Suzuki, K; Takeuchi, K; Umdeda, M, 1999)
"Clinical and endoscopic findings as well as Helicobacter pylori status, gastric secretion analysis, serum gastrin levels, nonsteroidal anti-inflammatory drug (NSAID) use, and objective testing of aspirin use by platelet cyclooxygenase activity were studied in 60 consecutive refractory patients with peptic ulcer and 54 matched nonrefractory controls."	3.69	Risk factors associated with refractory peptic ulcers. ( Esteva, F; Lanas, AI; Remacha, B; Sáinz, R, 1995)
"To compare the outcome of 76 patients who presented with severe peptic ulcer haemorrhage whilst taking nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin with that of 112 patients who were not taking these drugs and who developed peptic ulcer haemorrhage over the same time period."	3.69	The outcome of peptic ulcer haemorrhage in relation to consumption of nonsteroidal anti-inflammatory drugs or aspirin. ( Choudari, CP; Elton, RA; Palmer, KR, 1994)
"Because aspirin (ASA) may affect peptic ulcer healing through actions on platelets (for example, by inhibiting release of growth factors), human foreskin fibroblast mitogenesis was used for two bioassays (24-h growth with 3H-thymidine incorporation and 5- to 6-day cell proliferation) for serum derived from collagen-aggregated platelet-rich plasma (PRP) or platelet-poor plasma (PPP) or from clotted whole blood (WBS)."	3.69	Ingestion of aspirin prevents platelet-induced human fibroblast growth. Implications for peptic ulcer healing. ( Haggerty, P; Hirschowitz, BI; Lanas, A, 1994)
"05) correlation was found in the following associations: aspirin and multiple gastric ulcers, aspirin and severe erosive gastritis; non-steroidal antiinflammatory drugs and multiple duodenal ulcers, non-steroidal antiinflammatory drugs and mild erosive gastritis."	3.67	[Peptic lesions of the upper digestive tract and drugs. Prospective study]. ( Borel, GA; de Peyer, R; Gaillard, C; Loizeau, E, 1984)
"Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily."	3.67	Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989)
"Antacids containing aluminum hydroxide are protective for the stomach in that they prevent grossly visible mucosal necrosis and hemorrhages produced by noxious agents such as aspirin or absolute ethanol."	3.67	Antacid protection of gastric mucosa. ( Domschke, W; Hagel, J; Kaduk, B; Ruppin, H, 1986)
"We examined in a controlled study whether psychologic disturbances in men with peptic ulcer disease were related to other potential ulcer "risk factors" (serum pepsinogen concentrations, cigarette smoking, and intake of alcohol, aspirin, or coffee)."	3.67	Life events stress and psychosocial factors in men with peptic ulcer disease. II. Relationships with serum pepsinogen concentrations and behavioral risk factors. ( Feldman, M; Luther, J; Samloff, IM; Walker, P, 1988)
"Aspirin is generally regarded as a cause of gastric ulcer but the role of non-steroidal anti-inflammatory agents and paracetamol in the aetiology of peptic ulcer is unclear."	3.67	Peptic ulcer and non-steroidal anti-inflammatory agents. ( Dobson, AJ; Duggan, JM; Fahey, P; Johnson, H, 1986)
"In a survey of the published evidence linking aspirin ingestion to gastric mucosal damage an attempt has been made to assess the role of aspirin in the pathogenesis of acute and chronic gastric haemorrhage and peptic ulceration."	3.66	Reappraisal of the effects of aspirin on the stomach. ( Rees, WD; Turnberg, LA, 1980)
"A comparison of aspirin and acetaminophen consumption in 346 matched pairs of patients with hematemesis and melena and general population control subjects has shown associations between intake of both drugs and bleeding."	3.66	Analgesic intake and the risk of acute upper gastrointestinal bleeding. ( Coggon, D; Langman, MJ; Spiegelhalter, D, 1983)
"Studies with benoxaprofen in rheumatoid arthritis and osteoarthritis, conducted in more than 2000 patients, continue to demonstrate its safety and effectiveness."	3.66	An update on long-term efficacy and safety with benoxaprofen. ( Mikulaschek, WM, 1982)
" Taking aspirin is exceptional before rupture of esophageal varices."	3.65	[Clinical aspects and course of drug-induced upper digestive hemorrhage]. ( Benarous, JJ; Frexinos, J; Legrand, G; Pascal, JP; Ribet, A; Suduca, P; Tournut, R, 1976)
"Smoking, heredity, aspirin ingestion, and various diseases are associated with increased prevalence of peptic ulcer disease."	3.65	Peptic ulcer disease. ( Isenberg, JI, 1975)
"Recurrent gastrojejunal ulceration is reported in three patients with histamine-fast achlorhydria."	3.65	Marginal ulcer in achlorhydric patients. ( Hirschowitz, BI; Tauxe, RV; Wright, LF, 1975)
"Hence, peptic ulcer is the ulcer of both the stomach and the duodenum."	3.01	A Review on Herbal Drugs Used in the Treatment of Peptic Ulcer. ( Ahmed, SI; Gogoi, HK; Kashyap, A; Maut, C; Roy, AJ, 2023)
" The long-term use of proton pump inhibitors (PPIs) is associated with adverse events."	2.90	Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. ( Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S, 2019)
" Adverse events (AEs) caused study withdrawal in 13."	2.82	Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. ( Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Scheiman, JM; Whellan, DJ, 2016)
"Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups."	2.82	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016)
"Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts."	2.82	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016)
" The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score."	2.79	A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. ( Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014)
"Many individuals with gastroduodenal ulcers require on-going, non-steroidal anti-inflammatory drug (NSAID) or anti-platelet therapy."	2.74	A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing. ( Aisenberg, J; Bamji, N; Bodian, C; Brooks, A; Cohen, L; Desai, J; Dikman, A; Miller, K; Sanyal, S; VON Althann, C; Whitson, M, 2009)
"Aspirin was most commonly used (43%)."	2.69	Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. ( Fock, KM; Khor, JL; Machin, D; Ng, TM; Sim, CS; Tan, AL; Teo, EK, 2000)
"Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1."	2.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
"The misoprostol/aspirin-treated group had significantly (P < 0."	2.67	Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. ( Boudrieau, RJ; Labato, MA; Matz, ME; Murtaugh, RJ, 1993)
"The aspirin component was terminated earlier than scheduled, and the preliminary findings were published."	2.66	Final report on the aspirin component of the ongoing Physicians' Health Study. ( , 1989)
"Misoprostol was statistically significantly superior to both sucralfate (p = 0."	2.66	A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. ( Dickson, B; Gustitus, L; Lanza, F; Peace, K; Rack, MF, 1988)
" Unfortunately, they are often associated with dyspepsia, and this troublesome side-effect is a limitation to their chronic use by many patients."	2.66	Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal intolerance and major bleeding--or do they? ( Tenenbaum, J, 1987)
" Despite substantial clinical heterogeneity across the studies, including types of H2 blockers, dosing of ASA and underlying conditions, no statistical heterogeneity was observed."	2.48	Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review and meta-analysis. ( Al-Omran, M; Alateeq, A; Mamdani, M; Straus, SE; Tashkandi, M; Tricco, AC, 2012)
"This review explores the results of clinical studies on the influence of the combination esomeprazole (ESA) and ASA on pharmacokinetic (PK) parameters, and the role for such combination in prevention of CV events in patients at risk of gastric ulcers."	2.48	Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. ( Bardou, M; Barkun, AN; Goirand, F; Hamza, S; Le Ray, I, 2012)
"Medline search for articles published up to 2007, using the keywords acetylsalicylic acid, aspirin, NSAIDs, cyclooxygenase 2, adverse effects, ulcer, and cardiovascular."	2.46	Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. ( van de Laar, MA; Vonkeman, HE, 2010)
" Given their long-term use by millions of patients, there is a substantial impact at the population level of these complications."	2.45	Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. ( Arora, G; Singh, G; Triadafilopoulos, G, 2009)
" The risk of ulcer complications can however be reduced, and perhaps completely removed, by using the lowest dose of the least toxic member of the class."	2.42	Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. ( Langman, MJ, 2003)
"Aspirin is an independent risk factor for UGI tract injury, even at the low doses used for cardiovascular prophylaxis."	2.42	Challenges in managing NSAID-associated gastrointestinal tract injury. ( Goldstein, JL, 2004)
" Patients with GI adverse events during coxib therapy require co-therapy with acid suppression or prostaglandin analogue."	2.41	[Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors]. ( Prónai, L, 2001)
" Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension."	2.41	Gastrointestinal safety of COX-2 specific inhibitors. ( Hawkey, CJ; Jones, JI, 2001)
" When used long term, aspirin has significant adverse effects and is poorly tolerated."	2.40	Use and safety of aspirin in the chemoprevention of colorectal cancer. ( Singh, AK; Trotman, BW, 1998)
"Over 80% of recurrences are infrequent and can be treated when they occur n 20% of ulcer patients have 3 recurrences/yr, ulcer complications, or such poor health that recurrence might prove fatal."	2.38	Maintenance therapy for peptic ulcer--who needs it? ( McCarthy, DM, 1993)
" Some of the newer NSAIDs seem at normal dosage to be far less damaging than traditional ASA or indomethacin."	2.37	Gastroduodenal damage due to drugs, alcohol and smoking. ( Domschke, S; Domschke, W, 1984)
"Acute gastroduodenal ulcer bleeding is a life-threatening condition."	1.91	[Recent aspects of pharmaceutical and endoscopic treatment of acute gastroduodenal ulcer bleeding]. ( Rácz, I, 2023)
"Laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery is a safe and effective procedure for patients with severe obesity."	1.46	Is Daily Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric Bypass for Obesity Surgery? ( Amin, N; Anvari, M; Gmora, S; Hong, D; Kang, X; Tiboni, M, 2017)
"Aspirin was used by 16/48 (33."	1.40	Bleeding gastroduodenal ulcers in patients without Helicobacter pylori infection and without exposure to non-steroidal anti-inflammatory drugs. ( Djuranović, S; Golubović, M; Milicić, B; Smolović, B; Stanisavljević, D; Vucković, L, 2014)
"Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin."	1.40	Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014)
"Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode."	1.40	Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. ( Hong, MJ; Jin, CJ; Kim, JH; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2014)
"Aspirin was the most frequently prescribed adjoining non-anti-hypertensive drugs (39."	1.33	Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. ( Balogun, OB; Yusuff, KB, 2005)
"Diclofenac and aspirin were most common NSAIDs associated with peptic ulcers in 32."	1.33	Frequency of NSAID induced peptic ulcer disease. ( Abid, S; Hamid, S; Islam, M; Islam, S; Jafri, W; Yakoob, J, 2006)
"Uninvestigated dyspepsia is common in family practice."	1.32	The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Daniels, S; Escobedo, S; Sinclair, P; Thomson, AB; Van Zanten, SJ; White, RJ, 2003)
"Gastroduodenal ulcers were found in 94 (44%) of the patients; two thirds of the users and one third of the non-users."	1.29	[Use of acetylsalicylic acid and other antiphlogistics in hematemesis/melena]. ( Aabakken, L; Breckan, RK, 1994)
" There was a linear dose-response curve that was steeper in women than in men."	1.29	Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. ( Dobson, A; Henry, D; Turner, C, 1993)
"Aspirin alone was the least frequently ingested."	1.26	Analgesic ingestion and chronic peptic ulcer. ( Ariotti, DE; Fenton, BH; MacLennan, R; McIntosh, JH; Piper, DW, 1981)

Research

Studies (538)

Authors

Clinical Trials (26)

Trial Overview

Trial Outcomes

All-cause Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	192 (35.69)	18.7374
1990's	48 (8.92)	18.2507
2000's	140 (26.02)	29.6817
2010's	139 (25.84)	24.3611
2020's	19 (3.53)	2.80

Authors	Studies
Lolli, ML	2
Cena, C	2
Medana, C	1
Lazzarato, L	2
Morini, G	2
Coruzzi, G	2
Manarini, S	1
Fruttero, R	2
Gasco, A	2
Jain, S	1
Tran, S	1
El Gendy, MA	1
Kashfi, K	1
Jurasz, P	1
Velázquez-Martínez, CA	1
Bourgeois, S	1
Carr, DF	1
Musumba, CO	1
Penrose, A	1
Esume, C	1
Morris, AP	1
Jorgensen, AL	1
Zhang, JE	1
Pritchard, DM	2
Deloukas, P	1
Pirmohamed, M	2
Nguyen, TNM	1
Sha, S	1
Chen, LJ	1
Holleczek, B	1
Brenner, H	1
Schöttker, B	1
Kinoshita, Y	3
Kato, M	3
Sugizaki, K	1
Ikeuchi, S	1
Hawkey, C	2
Avery, A	1
Coupland, CAC	1
Crooks, C	1
Dumbleton, J	1
Hobbs, FDR	1
Kendrick, D	1
Moore, M	1
Morris, C	1
Rubin, G	1
Smith, M	1
Stevenson, D	1
Yadlapati, R	2
Roy, AJ	2
Maut, C	2
Gogoi, HK	2
Ahmed, SI	2
Kashyap, A	2
Perisetti, A	1
Sharma, P	1
Borao Laguna, C	1
Lanas, A	19
Alhalabi, MM	1
Huang, J	1
Liao, F	1
Tang, J	1
Shu, X	1
Rácz, I	2
Nakamura, M	2
Kitazono, T	1
Kozuma, K	1
Sekine, T	1
Nakamura, S	2
Shiosakai, K	1
Iizuka, T	1
Scheiman, JM	9
Watanabe, T	2
Fujiwara, Y	1
Chan, FKL	1
Ahn, JY	1
Yang, SC	1
Wu, CK	1
Tai, WC	1
Liang, CM	1
Yao, CC	1
Wu, KL	1
Hsu, CN	1
Chuah, SK	2
Haastrup, PF	1
Hansen, JM	2
Søndergaard, J	1
Jarbøl, DE	1
Ghasemkhani, N	1
Tabrizi, AS	1
Namazi, F	1
Nazifi, S	1
Kamal, H	1
Sadr-Azodi, O	2
Engstrand, L	1
Brusselaers, N	1
Hatakeyama, Y	1
Horino, T	1
Matsumoto, T	2
Terada, Y	1
Okuhara, Y	1
Chen, WC	4
Lin, KH	2
Huang, YT	1
Tsai, TJ	3
Sun, WC	1
Wu, DC	1
Hsu, PI	5
Jawaid, H	1
Hussain, A	1
Imtiaz, F	1
Iwasawa, M	2
Wada, K	1
Takada, M	3
Brodie, MM	1
Newman, JC	1
Smith, T	1
Rockey, DC	1
Kawai, T	3
Oda, K	1
Funao, N	1
Nishimura, A	1
Matsumoto, Y	1
Mizokami, Y	4
Ashida, K	1
Sugano, K	8
Szabó, IL	1
Mátics, R	1
Hegyi, P	1
Garami, A	1
Illés, A	1
Sarlós, P	1
Bajor, J	1
Szűcs, A	1
Mosztbacher, D	1
Márta, K	1
Szemes, K	1
Csekő, K	1
Kővári, B	1
Rumbus, Z	1
Vincze, Á	2
Sugisaki, N	1
Iwakiri, R	3
Tsuruoka, N	1
Sakata, Y	3
Shimoda, R	2
Fujimoto, S	1
Eguchi, Y	1
Fujimoto, K	4
Sarri, GL	1
Grigg, SE	1
Yeomans, ND	5
Pantea, M	1
Negovan, A	1
Voidăzan, S	1
Macarie, M	1
Mocan, S	1
Băţagă, S	1
Sagami, K	1
Yokoyama, S	1
Hosomi, K	2
Pittayanon, R	1
Piyachaturawat, P	1
Rerknimitr, R	1
Prueksapanich, P	1
Chaitongrat, S	1
Lertsuwunseri, V	1
Srimahachota, S	1
Mahachai, V	1
Moayyedi, P	1
Eikelboom, JW	1
Bosch, J	1
Connolly, SJ	1
Dyal, L	1
Shestakovska, O	1
Leong, D	1
Anand, SS	1
Störk, S	1
Branch, KRH	1
Bhatt, DL	2
Verhamme, PB	1
O'Donnell, M	1
Maggioni, AP	1
Lonn, EM	1
Piegas, LS	1
Ertl, G	1
Keltai, M	1
Cook Bruns, N	1
Muehlhofer, E	1
Dagenais, GR	1
Kim, JH	2
Hori, M	2
Steg, PG	1
Hart, RG	1
Diaz, R	1
Alings, M	1
Widimsky, P	1
Avezum, A	1
Probstfield, J	1
Zhu, J	1
Liang, Y	1
Lopez-Jaramillo, P	1
Kakkar, A	1
Parkhomenko, AN	1
Ryden, L	1
Pogosova, N	1
Dans, A	1
Lanas, F	1
Commerford, PJ	1
Torp-Pedersen, C	1
Guzik, T	1
Vinereanu, D	1
Tonkin, AM	1
Lewis, BS	1
Felix, C	1
Yusoff, K	1
Metsarinne, K	1
Fox, KAA	1
Yusuf, S	1
van der Elst, K	1
Oortgiesen, B	1
Kruik-Kollöffel, W	1
Hoogendoorn, M	1
Hofma, S	1
van Roon, E	1
Tamura, A	2
Murakami, K	2
Kadota, J	2
Iwamoto, J	4
Saito, Y	3
Honda, A	3
Matsuzaki, Y	3
Amagase, K	2
Yoshida, Y	1
Hara, D	1
Murakami, T	1
Takeuchi, K	3
Jiang, Z	1
Wu, H	1
Duan, Z	1
Wang, Z	1
Hu, K	1
Ye, F	1
Zhang, Z	1
Tricco, AC	1
Alateeq, A	1
Tashkandi, M	1
Mamdani, M	1
Al-Omran, M	1
Straus, SE	1
Uemura, N	1
Hiraishi, H	3
Shimada, K	1
Goto, S	2
Uchiyama, S	2
Okada, Y	2
Origasa, H	1
Ikeda, Y	1
Satoh, H	1
Hedberg, J	1
Sundström, J	1
Thuresson, M	1
Aarskog, P	1
Oldgren, J	1
Bodegard, J	1
Watari, I	1
Oka, S	1
Tanaka, S	1
Aoyama, T	1
Imagawa, H	1
Shishido, T	1
Yoshida, S	2
Chayama, K	1
Kim, SG	1
Jung, HK	2
Lee, HL	1
Jang, JY	1
Lee, H	1
Kim, CG	1
Shin, WG	1
Shin, ES	1
Lee, YC	2
Charpignon, C	1
Lesgourgues, B	1
Pariente, A	1
Nahon, S	1
Pelaquier, A	1
Gatineau-Sailliant, G	1
Roucayrol, AM	1
Courillon-Mallet, A	1
Choi, MG	1
Lin, JT	1
Miwa, H	2
Chiang, CE	1
Chiba, T	1
Fukushima, Y	1
Kim, HS	1
Chang, CY	1
Date, M	1
Guo, X	1
Wang, J	1
Wang, Y	2
Ma, H	1
Hao, X	1
Li, J	1
Fujimoto, M	1
Ma, B	1
Hang, L	1
Chen, G	1
Du, Y	1
Tozawa, K	1
Oshima, T	1
Okugawa, T	1
Ogawa, T	1
Ohda, Y	1
Tomita, T	1
Hida, N	1
Fukui, H	1
Hori, K	1
Watari, J	1
Smolović, B	1
Stanisavljević, D	1
Golubović, M	1
Vucković, L	1
Milicić, B	1
Djuranović, S	1
Endo, H	1
Sakai, E	1
Taniguchi, L	1
Kessoku, T	1
Komiya, Y	1
Ezuka, A	1
Kawamura, H	1
Taguri, M	1
Higurashi, T	1
Ohkubo, H	1
Yamada, E	1
Takahashi, H	2
Inamori, M	2
Maeda, S	1
Sakaguchi, T	2
Hata, Y	1
Nagase, H	1
Nakajima, A	2
Sakamoto, Y	1
Shimoyama, T	1
Nakagawa, S	1
Mikami, T	1
Fukuda, S	1
Pottegård, A	1
Kviesgaard, AK	1
Hesse, U	1
Moreno, SI	1
González-Pérez, A	2
Sáez, ME	1
Johansson, S	2
Nagy, P	3
García Rodríguez, LA	4
Sostres, C	2
Gargallo, CJ	2
Lim, YJ	1
Hong, SJ	1
Ahn, DG	1
Kim, BJ	1
Kim, JW	3
Kim, JG	1
Wang, PY	1
Chen, HP	1
Chen, A	1
Tsay, FW	3
Lai, KH	4
Kao, SS	1
Kuo, CH	1
Peng, NJ	1
Tseng, HH	1
Shimokobe, K	2
Ikegami, T	2
Marcum, ZA	1
Hanlon, JT	1
Strotmeyer, ES	1
Newman, AB	1
Shorr, RI	1
Simonsick, EM	1
Bauer, DC	1
Boudreau, R	1
Donohue, JM	1
Perera, S	1
Li, YD	1
Chiang, PH	1
Chan, HH	2
Tsai, WL	1
Wang, EM	1
Cheng, JS	1
Kim, JJ	2
Kim, N	3
Kawasaki, K	1
Kurahara, K	1
Yanai, S	1
Kochi, S	1
Fuchigami, T	1
Hong, MJ	1
Lee, SY	1
Sung, IK	2
Park, HS	1
Shim, CS	1
Jin, CJ	1
Laursen, SB	1
Jørgensen, HS	1
Schaffalitzky de Muckadell, OB	1
Ruigómez, A	1
Martín-Pérez, M	1
Rodríguez, LA	1
Takeuchi, T	2
Ota, K	1
Harada, S	1
Kojima, Y	1
Inoue, T	1
Fujita, T	3
Azuma, T	3
Higuchi, K	2
Shiotani, A	7
Murao, T	3
Fujita, Y	1
Fujimura, Y	1
Sakakibara, T	6
Nishio, K	1
Haruma, K	7
Cheng, Y	1
Lin, J	1
Liu, J	1
Yan, W	1
Zhang, M	1
Veldhuyzen van Zanten, S	2
Baldycheva, I	1
Svedberg, LE	3
Warlé-van Herwaarden, MF	1
Koffeman, AR	1
Valkhoff, VE	2
't Jong, GW	1
Kramers, C	1
Sturkenboom, MC	3
De Smet, PA	1
Chernukha, IM	1
Bogatyrev, AN	1
Dydykin, AS	1
Aslanova, MA	1
Fedulova, LV	1
Mo, C	1
Sun, G	1
Lu, ML	1
Zhang, L	1
Wang, YZ	1
Sun, X	1
Yang, YS	1
Satoh, K	3
Tanabe, H	1
Ichiishi, E	1
Ando, K	1
Feng, A	1
Chuang, E	1
Wu, SH	1
Wang, JC	1
Chang, SN	2
Lin, CL	1
Kao, CH	1
Kim, SH	2
Jung, JT	1
Kwon, JG	1
Kim, EY	1
Lee, DW	1
Jeon, SW	2
Park, KS	1
Lee, SH	2
Park, JB	1
Ha, CY	1
Park, YS	2
Iijima, K	1
Shimosegawa, T	1
Goldstein, JL	3
Whellan, DJ	1
Cryer, BL	2
Eisen, GM	1
Fort, JG	1
Wu, Y	1
Hu, Y	1
You, P	1
Chi, YJ	1
Zhou, JH	1
Zhang, YY	1
Liu, YL	1
Vaduganathan, M	1
Liu, Y	1
Hsieh, WH	1
Doros, G	1
Cohen, M	1
Schnitzer, TJ	1
Shook, TL	1
Lapuerta, P	1
Goldsmith, MA	1
Laine, L	3

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763]	Phase 3	621 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247]	Phase 3	439 participants (Actual)	Interventional	2012-03-31	Completed
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Pilot Study[NCT04289012]		300 participants (Actual)	Interventional	2019-11-07	Completed
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864]		22,000 participants (Anticipated)	Interventional	2021-11-17	Recruiting
Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study[NCT02166008]	Phase 2/Phase 3	142 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin[NCT01069939]	Phase 3	427 participants (Actual)	Interventional	2010-02-28	Completed
Risk of Uncomplicated Peptic Ulcer in the General Population[NCT01888588]		4,000 participants (Actual)	Observational	2012-09-30	Completed
A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers[NCT00995410]	Phase 3	380 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921]	Phase 3	5,000 participants (Anticipated)	Interventional	2007-12-31	Terminated (stopped due to Terminated by Sponsor)
Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186]	Phase 3	264 participants (Actual)	Interventional	2011-01-31	Completed
Falciformopexy for Treatment Perforated Peptic[NCT05715450]		25 participants (Anticipated)	Interventional	2023-05-30	Not yet recruiting
Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases: A Multicenter, Randomized, Double-blinded, Controlled Trial[NCT03320538]		360 participants (Anticipated)	Interventional	2017-07-10	Recruiting
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]		228 participants (Actual)	Interventional	2012-01-31	Completed
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012]		51 participants (Actual)	Interventional	2013-11-30	Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]		101 participants (Actual)	Interventional	2012-07-31	Completed
[NCT00153725]		156 participants	Interventional	2003-02-28	Completed
A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727]	Phase 3	2,426 participants (Actual)	Interventional	2007-02-28	Completed
Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer[NCT01037491]		200 participants (Anticipated)	Interventional	2009-10-31	Recruiting
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]	Phase 4	20 participants (Actual)	Interventional	2016-06-26	Completed
Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762]	Phase 4	29 participants (Actual)	Interventional	2015-06-30	Completed
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703]	Phase 3	6,000 participants	Interventional	2002-06-27	Completed
A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191]	Phase 3	528 participants (Actual)	Interventional	2003-02-05	Completed
A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445]	Phase 3	23,498 participants (Actual)	Interventional	2003-01-31	Completed
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479]	Phase 3	39,876 participants (Actual)	Interventional	1992-09-30	Completed
[NCT00000500]	Phase 3	0 participants	Interventional	1981-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	138

Modified Lanza scale attributes the degree of gastric mucosal lesion, graded on a 5 point scale (0=No hemorrhage, no erosion, 1=One hemorrhage or one erosions, 2=2-10 hemorrhages or erosions, 3=11-25 hemorrhages or erosions, 4=More than 25 hemorrhages or erosions, or ulcer). Higher scores indicate greater severity of gastric mucosal lesion. (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week

Intervention	Scores on a scale (Mean)
Esomeprazole 20mg	-0.4
Placebo	1.3

"The severity of abdomen enlarged feeling at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Anorexia From Baseline to Last Measurement up to Week 48

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	18	141	9
Placebo	24	141	7

"The severity of anorexia at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	9	156	3
Placebo	10	153	9

"The severity of Discomfort in the stomach at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	13	150	5
Placebo	15	148	9

"The severity of epigastric pain at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	11	153	4
Placebo	16	145	11

"The severity of heartburn at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Change in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	7	158	3
Placebo	6	154	12

"The severity of Nausea and/or Vomiting at baseline and the last measurement up to 48 weeks was obtained (None, Mild, Moderate, Severe). If the value at the last was better in a participant, the participant was categorized into Improved. If the value was same, categorised into Unchanged. If the value was worsened, categorise into Worsened." (NCT01069939)
Timeframe: Up to 48 weeks (Baseline to last measurement)

Number of Participants With Adverse Events

Intervention	Participants (Number)
	Improved	Unchanged	Worsened
Esomeprazole 20mg	8	160	0
Placebo	5	154	13

Participants who had at least adverse events (AE) which occurred after receiving study drug were counted. (NCT01069939)
Timeframe: Up to 70 weeks at the longest

Number of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.

Intervention	Participants (Number)
	Adverse event	Adverse event (Frequency>=5%)	Death	Serious adverse event other than death	Adverse event leading to discontinuation of study	Drug-related adverse event	Severe adverse event
Esomeprazole 20mg	155	70	0	17	17	31	7
Placebo	139	53	0	15	22	29	10

Endoscopy was conducted at 12, 24, 36 and 48 weeks after randomisation. At the endoscopy, participants was evaluated whether they have reflux esophagitis or not. (NCT01069939)
Timeframe: 12, 24, 36 and 48 weeks

Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.

Intervention	Participants (Number)
	12 weeks	24 weeks	36 weeks	48 weeks
Esomeprazole 20mg	0	1	0	0
Placebo	9	6	3	0

Assessments for occurrence of gastric and/or duodenal ulcers were performed every 12 weeks after randomisation. The numbers of participants with recurrence of gastric and/or duodeal ulcers were analysed every 12 weeks up to 48 weeks. (NCT01069939)
Timeframe: From randomisation to up to 48 weeks (Maximum follow-up period at the interim analysis)

Number of Subjects Monitored for Long-term Safety of PA32540

Intervention	Participants (Number)
	0 - 12 weeks	13 - 24 weeks	25 - 36 weeks	37 - 48 weeks
Esomeprazole 20mg	1	1	0	0
Placebo	16	4	2	0

Incidence of adverse events and monitoring vital signs and clinical laboratory values. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). (NCT00995410)
Timeframe: 12 months

Most Frequent Treatment Emergent Adverse Events Leading to Study Drug Discontinuation

Intervention	participants (Number)
PA32540 Tablet	379

Most Frequent (≥ 1%) Treatment Emergent Adverse Events by System Organ Class leading to Discontinuation (NCT00995410)
Timeframe: 12 months

Number of Participants With Healed Peptic Ulcer

Intervention	participants (Number)
	Subjects with any AE Leading to Discontinuation	Gastrointestinal disorders	Neoplasms benign, malignant and unspecified	Cardiac Disorders	Investigations
PA32540 Tablet	51	15	7	6	6

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Number of Participants in Which H. Pylori Was Eradicated

Intervention	participants (Number)
Histamine-2 Receptor Antagonist Group	106
Placebo Group	101

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.

Number of Participants With Ulcer Recurrence

Intervention	participants (Number)
Esomeprazole+Amox+Levo+Tetra	13
Esomeprazole+Amox+Levo	21

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.

Intervention	participants (Number)
Proton Pump Inhibitor Group	1
Histamine-2 Receptor Antagonist Group	7

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.

Intervention	participants (Number)
Esomeprazole 40 mg	591
Esomeprazole 20 mg	577
Placbo	504

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

Number of Participants With Gastric and/or Duodenal Erosions.

Intervention	participants (Number)
Esomeprazole 40 mg	554
Esomeproazole 20 mg	537
Placebo	451

(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.

Intervention	participants (Number)
Esomeprazole 40	214
Esomeproazole 20	213
Placebo	380

The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).

Intervention	percentage of participants (Number)
Esomeprazole 40	1.1
Esomeproazole 20	0.75
Placebo	4.1

The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.

Intervention	percentage of participants (Number)
Esomeprazole 40	1.35
Esomeproazole 20	1
Placebo	6.58

The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Intervention	participants (Number)
	Total invasive cancer	Cancer death
Aspirin + Vitamin E	716	152
Aspirin Only	722	132
Both Placebos	706	143
Vitamin E Only	721	156

Intervention	Participants (Number)
	Major cardiovascular event	Stroke	Myocardial infarction	Cardiovascular death
Aspirin + Vitamin E	232	108	102	54
Aspirin Only	245	113	96	66
Both Placebos	272	133	99	74
Vitamin E Only	250	133	94	52

Article	Year
A Review on Herbal Drugs Used in the Treatment of Peptic Ulcer. Current drug discovery technologies, 2023, Volume: 20, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Humans; Inflammation; Pep	2023
A Review on Herbal Drugs Used in the Treatment of Peptic Ulcer. Current drug discovery technologies, 2023, Volume: 20, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Humans; Inflammation; Pep	2023
A Review on Herbal Drugs Used in the Treatment of Peptic Ulcer. Current drug discovery technologies, 2023, Volume: 20, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Humans; Inflammation; Pep	2023
A Review on Herbal Drugs Used in the Treatment of Peptic Ulcer. Current drug discovery technologies, 2023, Volume: 20, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Humans; Inflammation; Pep	2023
Advances in the pharmacotherapeutic management of refractory peptic ulcers. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylori; Huma	2023
Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. Journal of gastroenterology, 2020, Volume: 55, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsule Endoscopy; Gas	2020
Prevention of Peptic Ulcer Associated with Aspirin and Antiplatelet Agent. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2020, 11-25, Volume: 76, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Helicobacter Infections; Helico	2020
PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis. Journal of gastrointestinal and liver diseases : JGLD, 2017, Volume: 26, Issue:4 Topics: Aspirin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans	2017
Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:3 Topics: Aspirin; Databases, Bibliographic; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans;	2019
Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:3 Topics: Aspirin; Databases, Bibliographic; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans;	2019
Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:3 Topics: Aspirin; Databases, Bibliographic; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans;	2019
Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:3 Topics: Aspirin; Databases, Bibliographic; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans;	2019
[Proton pump inhibitors when using clopidogrel: balance between necessity and disadvantages]. Nederlands tijdschrift voor geneeskunde, 2019, 05-24, Volume: 163 Topics: Aspirin; Clopidogrel; Drug Interactions; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrh	2019
Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World journal of gastroenterology, 2013, Mar-21, Volume: 19, Issue:11 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1;	2013
Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review and meta-analysis. Open medicine : a peer-reviewed, independent, open-access journal, 2012, Volume: 6, Issue:3 Topics: Aspirin; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Peptic Ulcer; Platelet Aggre	2012
Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World journal of gastroenterology, 2014, Jul-28, Volume: 20, Issue:28 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Helicobacter Inf	2014
Helicobacter pylori infection in nonsteroidal anti-inflammatory drug users. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Volume: 64, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylori; Huma	2014
Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: a post-hoc analysis of the OBERON trial. International journal of cardiology, 2015, Mar-01, Volume: 182 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Esomeprazole; Ga	2015
Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World journal of gastroenterology, 2015, May-07, Volume: 21, Issue:17 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Cytoprotection; Humans; O	2015
Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users. Current pharmaceutical design, 2015, Volume: 21, Issue:35 Topics: Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Platel	2015
Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use. Current pharmaceutical design, 2015, Volume: 21, Issue:35 Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Helicobacter Infectio	2015
[Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Jun-25, Volume: 67, Issue:6 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Membrane Permeability;	2016
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in experimental medicine and biology, 2017, Volume: 906 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage	2017
Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Seminars in arthritis and rheumatism, 2010, Volume: 39, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Patient Satisfaction; Peptic Ulcer; Random	2010
Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary pharmacology & therapeutics, 2009, May-01, Volume: 29, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Female; Helicobacter Infections	2009
[Non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury in Japan]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Histamine H2 Antagoni	2009
Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009, Volume: 7, Issue:7 Topics: Anti-Inflammatory Agents; Aspirin; Humans; Peptic Ulcer; Proton Pump Inhibitors	2009
Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2 Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pi	2009
Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito	2009
Differences in peptic ulcer between the East and the West. Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Resistance, Bacterial; Glo	2009
Gastroduodenal mucosal defense. Current opinion in gastroenterology, 2009, Volume: 25, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bicarbonates; Duodenum; Gastric Mucosa; Helicobact	2009
Peptic ulcer disease. Lancet (London, England), 2009, Oct-24, Volume: 374, Issue:9699 Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Biopsy; Gastroscopy;	2009
Optimal management of peptic ulcer disease in the elderly. Drugs & aging, 2010, Jul-01, Volume: 27, Issue:7 Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; He	2010
Aspirin-induced peptic ulcer and genetic polymorphisms. Journal of gastroenterology and hepatology, 2010, Volume: 25 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cyclooxygenase 1; C	2010
[The present state and problem of gastric ulcer caused by low-dose aspirin]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:11 Topics: Aged; Aspirin; Humans; Peptic Ulcer	2010
[The risk factors for aspirin induced peptic ulcer]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Pep	2010
[Influence of H. pylori infection on upper gastrointestinal damage]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:11 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylor	2010
[Role of proton pump inhibitor in the management of low dose aspirin related ulcerations]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Middle Aged; Peptic Ulcer; Proton Pu	2010
[A genetic background of ulcer diseases induced by NSAID/aspirin]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Humans; Middle Aged; Peptic Ulce	2010
[Strategy to manage low dose aspirin-induced gastrointestinal injury]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:2 Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid	2011
[Low-dose aspirin (LDA)/nonsteroidal anti-inflammatory drugs(NSAIDs)-induced gastrointestinal injury in Japan]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Japan; Peptic Ulcer	2011
[Management of NSAIDs and low-dose-aspirin-induced ulcer in patients with cerebral infarction]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Humans; Peptic Ulcer	2011
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:4 Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combin	2011
Acid-NSAID/aspirin interaction in peptic ulcer disease. Digestive diseases (Basel, Switzerland), 2011, Volume: 29, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Gastric Acid	2011
Acetylsalicylic acid/esomeprazole fixed-dose combination. Drugs & aging, 2012, Mar-01, Volume: 29, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsules; Cardiovascular Diseas	2012
Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding. European journal of internal medicine, 2012, Volume: 23, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Pl	2012
[Prevention and treatment of gastric mucosal injury in patients taking low-dose aspirin]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 7 Topics: Aspirin; Gastric Mucosa; Humans; Peptic Ulcer	2011
Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Diseases; Gastrointestinal Hemorr	2012
Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:2 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseas	2012
Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:9 Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Drug Interactions; Esomeprazole; Humans; Peptic	2012
One hundred years of NSAID gastropathy: are coxibs the answer? Reviews in gastroenterological disorders, 2001, Volume: 1, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Gastrointestinal Diseas	2001
[Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]. Presse medicale (Paris, France : 1983), 2002, Sep-28, Volume: 31, Issue:31 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitor	2002
Mandate to modify a medicinal mantra: maybe not yet? Gastroenterology, 2003, Volume: 124, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cardiovascular System; Drug Ad	2003
Helicobacter pylori-negative peptic ulcer. What is its aetiopathogenesis and treatment? Revista espanola de enfermedades digestivas, 2002, Volume: 94, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; False Negative Reactions; Helicobacter Infections;	2002
[The future of peptic ulcer disease without Helicobacter]. Praxis, 2003, Mar-19, Volume: 92, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin	2003
Non-steroidal anti-inflammatory drug-induced gastroduodenal toxicity and Helicobacter pylori. The Israel Medical Association journal : IMAJ, 2003, Volume: 5, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Division; Clinical Trials as Topic	2003
[Gastrointestinal complications of nonsteroidal anti-inflammatory drugs and low-dose aspirin]. Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:5 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Cyclooxygenase Inhi	2003
Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert opinion on drug safety, 2002, Volume: 1, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru	2002
[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. Zeitschrift fur Gastroenterologie, 2003, Volume: 41, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Gastrointestinal	2003
Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundamental & clinical pharmacology, 2003, Volume: 17, Issue:4 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Drug Inte	2003
The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Reviews in gastroenterological disorders, 2003, Volume: 3 Suppl 4 Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Humans; Omeprazole; Peptic Ul	2003
Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Alimentary pharmacology & therapeutics, 2004, Volume: 19 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylori; Huma	2004
Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion, 2004, Volume: 69 Suppl 1 Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Digesti	2004
Aspirin in the XXI century: its major clinical impact, novel mechanisms of action, and new safer formulations. Gastroenterology, 2004, Volume: 127, Issue:1 Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Peptic Ul	2004
[Impact of Helicobacter pylori infection on the risk of gastro-duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs]. Gastroenterologie clinique et biologique, 2004, Volume: 28 Spec No 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Hemorrhage; Helicobacter Infectio	2004
[Prevention of gastroduodenal complications in patients taking low-dose aspirin]. Gastroenterologie clinique et biologique, 2004, Volume: 28 Spec No 3 Topics: Aspirin; Drug Interactions; Humans; Peptic Ulcer; Platelet Aggregation Inhibitors; Risk Factors	2004
NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug safety, 2005, Volume: 28, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Apoptosis; Aspirin; Gastric Aci	2005
[NSAIDs for therapy of rheumatoid arthritis. Introduction]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Cyclooxy	2005
Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications. Postgraduate medicine, 2005, Volume: 117, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dyspepsia; Gastrointest	2005
[Gastroenterology in the elderly]. Praxis, 2005, Nov-30, Volume: 94, Issue:48 Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N	2005
[Relationship between NSAIDs and H. pylori in peptic ulcer diseases--is the eradication of H. pylori recommended in NSAIDs ulcer?]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Helicobacter Infections;	2005
Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention. Reviews in gastroenterological disorders, 2005, Volume: 5 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pro	2005
Peptic ulcer disease today. Nature clinical practice. Gastroenterology & hepatology, 2006, Volume: 3, Issue:2 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxy	2006
Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression. Alimentary pharmacology & therapeutics, 2006, Mar-15, Volume: 23, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Gastrins; Gastroesoph	2006
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World journal of gastroenterology, 2006, Jun-28, Volume: 12, Issue:24 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova	2006
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (London, England), 2007, Feb-10, Volume: 369, Issue:9560 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge	2007
Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Interactive cardiovascular and thoracic surgery, 2007, Volume: 6, Issue:4 Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicin	2007
The COX 2 selective inhibitors: what the newspapers have not told you. Bulletin of the NYU hospital for joint diseases, 2007, Volume: 65, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis, Rheumatoid; Aspirin; Blood Press	2007
Improving the gastrointestinal tolerability of aspirin in older people. Clinical interventions in aging, 2006, Volume: 1, Issue:1 Topics: Aged; Aspirin; Gastrointestinal Diseases; Humans; Peptic Ulcer	2006
Update in treatment of peptic ulcer disease. Missouri medicine, 1984, Volume: 81, Issue:11 Topics: Adult; Aged; Alcohol Drinking; Aluminum; Antacids; Anti-Ulcer Agents; Aspirin; Bismuth; Cimetidine;	1984
Epidemiology of peptic ulcer disease. Clinics in gastroenterology, 1984, Volume: 13, Issue:2 Topics: Adrenal Cortex Hormones; Aspirin; Caffeine; Cross-Sectional Studies; Diet; Ethanol; Female; Hospital	1984
Gastroduodenal damage due to drugs, alcohol and smoking. Clinics in gastroenterology, 1984, Volume: 13, Issue:2 Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Aspirin; Ethanol; Gastric Mucosa; Gastrointestinal	1984
[Drug-induced lesions in the upper gastrointestinal tract]. Medizinische Monatsschrift fur Pharmazeuten, 1984, Volume: 7, Issue:8 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Arthritis, Rheumatoid; Aspirin; Cheilitis; Drug-Rela	1984
[The most common drugs considered harmful to the stomach, Clinical and endoscopic studies]. Recenti progressi in medicina, 1980, Volume: 68, Issue:1 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Aspirin; Dyspepsia; Fema	1980
Drug-induced peptic ulcer and upper gastrointestinal bleeding. British journal of hospital medicine, 1980, Volume: 23, Issue:2 Topics: Adrenal Cortex Hormones; Alcoholism; Animals; Aspirin; Diuretics; Emepronium; Female; Gastrointestin	1980
[Gastric lesions induced by anti-inflammatory drugs (author's transl)]. Gastroenterologie clinique et biologique, 1981, Volume: 5, Issue:1 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Aspirin; Gastrointestinal Hemorrhage; Humans; Pep	1981
Prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastropathy. Southern medical journal, 1995, Volume: 88, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastric Mucosa; Histamine H2 An	1995
Maintenance therapy for peptic ulcer--who needs it? Gastroenterologia Japonica, 1993, Volume: 28 Suppl 5 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Helicobacter Infections; Heli	1993
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. British journal of clinical pharmacology, 1993, Volume: 35, Issue:3 Topics: Aged; Aspirin; Cardiovascular Diseases; Digestive System; Female; Gastrointestinal Diseases; Gastroi	1993
Use and safety of aspirin in the chemoprevention of colorectal cancer. Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians, 1998, Volume: 9, Issue:2 Topics: Aspirin; Cerebral Hemorrhage; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Incidence; Pe	1998
Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Italian journal of gastroenterology and hepatology, 1999, Volume: 31 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; Gastroin	1999
[Digestive complications of aspirin]. La Revue de medecine interne, 2000, Volume: 21 Suppl 1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Digestive System;	2000
Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. The American journal of medicine, 2001, Jan-08, Volume: 110, Issue:1A Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cyclooxygenase I	2001
The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. The American journal of managed care, 2001, Volume: 7, Issue:1 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Dyspepsia; Histamine H2 Antagon	2001
[Safety of specific cyclo-oxygenase 2 inhibitors]. Nederlands tijdschrift voor geneeskunde, 2001, Jun-02, Volume: 145, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Inci	2001
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. The Journal of clinical investigation, 2001, Volume: 108, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova	2001
Epidemiology of NSAID-related gastroduodenal mucosal injury. Best practice & research. Clinical gastroenterology, 2001, Volume: 15, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc	2001
Upper gastrointestinal complications: the causes, consequences, and clinical outcomes. The American journal of managed care, 2001, Volume: 7, Issue:12 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Cyclooxygenase Inhibitor	2001
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo	2001
[Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors]. Orvosi hetilap, 2001, Sep-02, Volume: 142, Issue:35 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxyg	2001
Gastrointestinal safety of COX-2 specific inhibitors. Gastroenterology clinics of North America, 2001, Volume: 30, Issue:4 Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygena	2001
Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase	2001
[Neutrophil-endothelium interaction]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Adhesion; Cell Adhesion Molecules;	2002
[Chaperon-induction therapy for peptic ulcers]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carnosine; Gastric Mucosa; Heat-Shock Pro	2002
Management of peptic ulcer disease not related to Helicobacter. Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Histamine Antagonists;	2002
Founder's lecture: New concepts of the gastric mucosal barrier. American journal of surgery, 1977, Volume: 133, Issue:1 Topics: Acid-Base Equilibrium; Animals; Aspirin; Bile Acids and Salts; Diffusion; Gastric Juice; Gastric Muc	1977
[The gastric mucosa barrier and gastropathy]. Minerva chirurgica, 1978, May-15, Volume: 33, Issue:9 Topics: Alcoholic Beverages; Aspirin; Bile Acids and Salts; Gastric Juice; Gastric Mucosa; Histamine Release	1978
[Clinical pharmacology of acetylsalicylic acid]. Ceskoslovenska pediatrie, 1979, Volume: 34, Issue:1 Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Asthma; Female; Humans; Hydrolysis; Intestinal Absorp	1979
The role of the mucosal barrier in drug-induced gastric ulceration and erosions. The American journal of digestive diseases, 1976, Volume: 21, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; Ethanol; Gastric Juice; Gastric Mucosa;	1976
Analgesics and the stomach. The New Zealand medical journal, 1976, Aug-11, Volume: 84, Issue:569 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Indometha	1976
Non-steroidal anti-inflammatory drugs and peptic ulcer. Hepato-gastroenterology, 1992, Volume: 39 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Causality; Humans; Peptic Ulcer; Risk Factors	1992
Repair and healing of established gastric mucosal injury. Journal of clinical gastroenterology, 1991, Volume: 13 Suppl 1 Topics: Animals; Aspirin; Cell Movement; Ethanol; Gastric Mucosa; Peptic Ulcer; Rats; Wound Healing	1991
Mechanisms of gastroprotection. Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 174 Topics: Animals; Anti-Ulcer Agents; Aspirin; Eicosanoids; Ethanol; Gastric Mucosa; Humans; Mucus; Peptic Ulc	1990
Ulcerogenic drugs and upper gastrointestinal bleeding. Bailliere's clinical gastroenterology, 1988, Volume: 2, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastrointestinal Hemorrhage; Glucocorticoids; Huma	1988
[Gastric mucosa barrier and the effect of non-steroidal anti-inflammatory agents and corticosteroid hormones on the gastric and duodenal mucosa]. Vutreshni bolesti, 1988, Volume: 27, Issue:3 Topics: Animals; Aspirin; Duodenum; Gastric Mucosa; Glucocorticoids; Humans; Indomethacin; Intestinal Mucosa	1988
NSAID-induced gastric mucosal damage. American family physician, 1987, Volume: 35, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Female; Gastric Mucosa; Ga	1987
[Gastric mucin]. Leber, Magen, Darm, 1972, Volume: 2, Issue:7 Topics: Aspirin; Epithelial Cells; Epithelium; Gastric Juice; Gastric Mucins; Gastric Mucosa; Glycoproteins;	1972
Gastric mucus and the gastric mucous barrier. A review. American journal of surgery, 1969, Volume: 117, Issue:6 Topics: Adrenocorticotropic Hormone; Aspirin; Eating; Fasting; Gastric Mucosa; Gastritis; Histamine; Humans;	1969
The prostaglandins: their significance in clinical practice. Medical times, 1974, Volume: 102, Issue:12 Topics: Abortion, Induced; Anemia, Hemolytic; Animals; Aspirin; Asthma; Chemical Phenomena; Chemistry; Cycli	1974
The gut and arthritis. Rheumatology and rehabilitation, 1974, Volume: 13, Issue:2 Topics: Adrenal Cortex Hormones; Analgesics; Anti-Inflammatory Agents; Arthritis, Infectious; Arthritis, Rhe	1974
Etiology of peptic ulcer. The Practitioner, 1974, Volume: 213, Issue:1273 Topics: Anxiety Disorders; Aspirin; Bile Acids and Salts; Blood Group Antigens; Diet; Duodenal Ulcer; Female	1974
Peptic ulcer: a review of the recent literature in various clinical aspects. I. Gastroenterology, 1968, Volume: 54, Issue:4 Topics: Adult; Aspirin; Female; Gastric Juice; Humans; Infant, Newborn; Male; Middle Aged; Peptic Ulcer; Sto	1968
Gastroenterology in Australia, 1949-69. Postgraduate medical journal, 1970, Volume: 46, Issue:534 Topics: Animals; Aspirin; Australia; Colitis, Ulcerative; Copper; Gastric Juice; Gastroenterology; Gastroint	1970
Epidemiological evidence for the association of aspirin and acute gastrointestinal bleeding. Gut, 1970, Volume: 11, Issue:7 Topics: Alcohol Drinking; Animals; Ascorbic Acid Deficiency; Aspirin; Gastrointestinal Hemorrhage; Hematemes	1970
Gastric mucin and mucinous secretions. Canadian journal of surgery. Journal canadien de chirurgie, 1970, Volume: 13, Issue:4 Topics: Aspirin; Cortisone; Epithelium; Gastric Juice; Gastric Mucins; Gastric Mucosa; Gels; Glycoproteins;	1970
Aspirin, ethanol and the stomach. Australasian annals of medicine, 1970, Volume: 19, Issue:3 Topics: Absorption; Aspirin; Ethanol; Gastric Juice; Gastritis; Gastrointestinal Hemorrhage; Humans; Peptic	1970
[Modern views on peptic ulcers]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1970, Nov-01, Volume: 23, Issue:21 Topics: Alcohols; Aspirin; Duodenal Ulcer; Female; Gastric Mucosa; Gastrins; Humans; Male; Parasympatholytic	1970
Gastric mucosal barrier. Gastroenterology, 1971, Volume: 61, Issue:2 Topics: Aspirin; Atropine; Bile Acids and Salts; Biological Transport; Cell Membrane Permeability; Gastric A	1971
Ibuprofen. A review. The Practitioner, 1971, Volume: 207, Issue:241 Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials	1971

Article	Year
Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2022, 11-05, Volume: 400, Issue:10363 Topics: Aged; Anti-Bacterial Agents; Aspirin; Clarithromycin; Drug Therapy, Combination; Helicobacter; Helic	2022
In older patients receiving aspirin, Annals of internal medicine, 2023, Volume: 176, Issue:4 Topics: Aged; Aspirin; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Peptic Ulcer;	2023
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:9 Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Met	2019
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, Volume: 157, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relation	2019
Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC gastroenterology, 2013, Jul-04, Volume: 13 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsul	2013
Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut, 2014, Volume: 63, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asian People; Aspirin; Doub	2014
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. The West Indian medical journal, 2013, Volume: 62, Issue:2 Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactio	2013
A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Digestive diseases and sciences, 2014, Volume: 59, Issue:8 Topics: Adult; Alanine; Anti-Ulcer Agents; Aspirin; Clopidogrel; Double-Blind Method; Gastric Mucosa; Gastro	2014
Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. Journal of gastroenterology and hepatology, 2014, Volume: 29 Suppl 4 Topics: Aged; Anti-Ulcer Agents; Aspirin; Diterpenes; Famotidine; Female; Histamine H2 Antagonists; Humans;	2014
Decreased vascular endothelial growth factor expression is associated with cell apoptosis in low-dose aspirin-induced gastric mucosal injury. The American journal of the medical sciences, 2015, Volume: 349, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Coronary Disea	2015
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. Cardiovascular therapeutics, 2016, Volume: 34, Issue:2 Topics: Aged; Aspirin; Cardiovascular Diseases; Dosage Forms; Drug Combinations; Female; Humans; Male; Middl	2016
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2016, Apr-12, Volume: 67, Issue:14 Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia;	2016
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. Gastroenterology, 2017, Volume: 152, Issue:1 Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2	2017
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary clinical trials, 2016, Volume: 51 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect	2016
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. The American journal of gastroenterology, 2008, Volume: 103, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Double-Bli	2008
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing. Alimentary pharmacology & therapeutics, 2009, Apr-01, Volume: 29, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administ	2009
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2009, Jul-11, Volume: 374, Issue:9684 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me	2009
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010, Volume: 138, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010, Volume: 138, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010, Volume: 138, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2010
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010, Volume: 138, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2010
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Annals of internal medicine, 2010, Jan-05, Volume: 152, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster	2010
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World journal of gastroenterology, 2010, Nov-14, Volume: 16, Issue:42 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A	2010
Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart (British Cardiac Society), 2011, Volume: 97, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Esomeprazole; Female; Humans; Male; Midd	2011
Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopid	2011
Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. The American journal of gastroenterology, 2012, Volume: 107, Issue:7 Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Drug Therapy, Co	2012
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. Journal of gastroenterology, 2012, Volume: 47, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases;	2012
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As	2012
Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. Alimentary pharmacology & therapeutics, 2004, Feb-01, Volume: 19, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopidogrel; Female; Humans;	2004
Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:7 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer	2004
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. Alimentary pharmacology & therapeutics, 2004, Jul-01, Volume: 20, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 In	2004
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben	2004
Effect of high-dose aspirin on Helicobacter pylori eradication. Digestive diseases and sciences, 2005, Volume: 50, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Chronic Disease; Clarithromyc	2005
The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. The Journal of rheumatology, 2007, Volume: 34, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase 2 Inhi	2007
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Annals of internal medicine, 2007, Oct-16, Volume: 147, Issue:8 Topics: Aspirin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S	2007
Long-term safety of benoxaprofen. The Journal of rheumatology. Supplement, 1980, Volume: 6 Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoxazoles; Blood Urea Nitrogen; C	1980
Chili protects against aspirin-induced gastroduodenal mucosal injury in humans. Digestive diseases and sciences, 1995, Volume: 40, Issue:3 Topics: Adult; Aspirin; Capsaicin; Capsicum; Duodenoscopy; Feeding Behavior; Female; Gastric Mucosa; Gastrit	1995
[Dose-dependent side effects of acetylsalicylic acid therapy. Results of a prospective randomized clinical study in patients with peripheral arterial occlusive disease]. Medizinische Klinik (Munich, Germany : 1983), 1993, Oct-15, Volume: 88, Issue:10 Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dose-Response Relationship, Drug;	1993
Omeprazole ameliorates aspirin-induced gastroduodenal injury. Digestive diseases and sciences, 1994, Volume: 39, Issue:1 Topics: Adult; Aspirin; Double-Blind Method; Duodenum; Female; Gastric Mucosa; Humans; Male; Omeprazole; Pep	1994
Use of synthetic prostaglandin E1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. Journal of the American Veterinary Medical Association, 1993, Jan-15, Volume: 202, Issue:2 Topics: Animals; Aspirin; Diarrhea; Dog Diseases; Dogs; Double-Blind Method; Duodenoscopy; Female; Gastroint	1993
Transforming growth factor-alpha (TGF-alpha) levels in human proximal gastrointestinal epithelium. Effect of mucosal injury and acid inhibition. Digestive diseases and sciences, 1997, Volume: 42, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Biopsy, Needle; Cimetidi	1997
[Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study]. Arzneimittel-Forschung, 1997, Volume: 47, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duo	1997
[The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison]. Arzneimittel-Forschung, 1998, Volume: 48, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Cyclooxy	1998
Helicobacter pylori-positive peptic ulcer patients do not adapt to aspirin. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:9 Topics: Adaptation, Physiological; Adult; Aspirin; Cell Division; DNA; Female; Gastric Mucosa; Gastroscopy;	1998
Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:2 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Gastrointestinal	2000
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, Sep-13, Volume: 284, Issue:10 Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin;	2000
[Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid afte Arzneimittel-Forschung, 2002, Volume: 52, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Drug Combinations; Endoscopy; F	2002
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. The New England journal of medicine, 2002, Jun-27, Volume: 346, Issue:26 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A	2002
[75 mg roxatidine nocte protects human gastric mucosa against 300 mg acetylsalicylic acid nocte]. Zeitschrift fur Gastroenterologie, 1991, Volume: 29, Issue:11 Topics: Adult; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Gastric Mucosa; Humans; Int	1991
[Protection from gastroduodenal adverse effects of acetylsalicylic acid with ranitidine. An endoscopic controlled double-blind study of healthy subjects]. Arzneimittel-Forschung, 1991, Volume: 41, Issue:6 Topics: Adult; Aspirin; Double-Blind Method; Endoscopy, Gastrointestinal; Humans; Male; Peptic Ulcer; Raniti	1991
Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Annals of internal medicine, 1991, Feb-15, Volume: 114, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Alcoholism; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;	1991
Treatment of NSAID-induced gastroduodenal ulcers. Gastroenterology, 1990, Volume: 99, Issue:5 Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi	1990
Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Archives of internal medicine, 1989, Volume: 149, Issue:4 Topics: Adult; Aged; Alprostadil; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Double-Blind Method; Du	1989
[Effect of somatostatin and ranitidine in acute hemorrhage of the upper digestive tract]. Acta gastroenterologica Latinoamericana, 1989, Volume: 19, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Gastritis; Gastro	1989
Final report on the aspirin component of the ongoing Physicians' Health Study. The New England journal of medicine, 1989, 07-20, Volume: 321, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disor	1989
[Gastroduodenal lesions in rheumatoid arthritis. Evaluation and treatment]. Acta gastroenterologica Latinoamericana, 1988, Volume: 18, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid	1988
A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. The American journal of gastroenterology, 1988, Volume: 83, Issue:2 Topics: Alprostadil; Anti-Ulcer Agents; Aspirin; Duodenoscopy; Duodenum; Gastric Mucosa; Gastroscopy; Humans	1988
Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal intolerance and major bleeding--or do they? Clinical and investigative medicine. Medecine clinique et experimentale, 1987, Volume: 10, Issue:3 Topics: Administration, Rectal; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as T	1987
A comparison of the incidence of peptic ulceration for fenbufen, indomethacin and aspirin treated patients compared with the general population. The Journal of international medical research, 1986, Volume: 14, Issue:2 Topics: Actuarial Analysis; Anti-Inflammatory Agents; Aspirin; Clinical Trials as Topic; Humans; Indomethaci	1986
Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. The American journal of medicine, 1986, Apr-28, Volume: 80, Issue:4B Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth	1986
Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis. Annals of the rheumatic diseases, 1974, Volume: 33, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Dys	1974
Ibuprofen. A review. The Practitioner, 1971, Volume: 207, Issue:241 Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials	1971

aspirin and Gastroduodenal Ulcer